pep005 and Carcinoma

A wide range of treatments is now available for nonmelanoma skin cancer (NMSC), including 5-fluorouracil, ingenol mebutate, imiquimod, diclofenac, photodynamic therapy, methotrexate, cetuximab, vismodegib, and radiotherapy. All are associated with high clinical and histologic response rates. However, some tumors do not respond due to resistance, which may be primary or acquired. Study of the resistance processes is a broad area of research that aims to increase our understanding of the nature of each tumor and the biologic features that make it resistant, as well as to facilitate the design of new therapies directed against these tumors. In this article we review resistance to the authorized topical treatments for NMSC.

Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antigen-Presenting Cells; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Clinical Trials as Topic; Dermatologic Agents; Diclofenac; Diterpenes; Drug Resistance, Neoplasm; Fluorouracil; Humans; Imiquimod; Meta-Analysis as Topic; Neoplasm Proteins; Neoplastic Stem Cells; Skin Neoplasms